Request Deal Involvement

BioNTech to acquire CureVac for $1.25bn.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Covington & Burling

legal advisors

Covington & Burling

Loyens & Loeff

legal advisors

Loyens & Loeff

PJT Partners

financial advisors

PJT Partners

Hengeler Mueller

legal advisors

Hengeler Mueller

Latham & Watkins

legal advisors to financial advisors

Latham & Watkins

NautaDutilh

legal advisors

NautaDutilh

Skadden Arps Slate Meagher & Flom

legal advisors

Skadden Arps Slate Meagher & Flom

Goldman Sachs

financial advisors

Goldman Sachs

Sullivan & Cromwell

legal advisors to financial advisors

Sullivan & Cromwell

or

Principals

BIONTECH

bidder

BIONTECH

CUREVAC

target

CUREVAC

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite